Journal article · 2025 · Open access

Identification and Description of Regulatory and Health Technology Assessment Agencies’ Guidance Related to Patient Experience Data in North America, Europe, and Asia Pacific

Laure Delbecque, Juergen Zschocke, Ding Ding, Jiat Ling Poon, Carolina Alonzo, Nancy Gabriela Pérez, Shane Myrick, Jennifer N. Hill

Therapeutic Innovation & Regulatory Science, 59(6), 1394–1412 · Published 17 July 2025 · DOI 10.1007/s43441-025-00777-z

Open PDFView at the publisherCite this paper

In brief

“Identification and Description of Regulatory and Health Technology Assessment Agencies’ Guidance Related to Patient Experience Data in North America, Europe, and Asia Pacific” is a 2025 journal article by Laure Delbecque and 7 co-authors, published in Therapeutic Innovation & Regulatory Science. OpenAlex counts 1 citations as of 22 November 2026. It is open access under a CC BY licence: the full text is free to read at Therapeutic Innovation & Regulatory Science.

Citations
1
Most cited in
2026 (1)
Field-weighted impact
0.51
References
17
Authors
8

Abstract

OBJECTIVES: To identify and describe patient experience data (PED)-related guidance issued by regulatory and health technology assessment (HTA) agencies in North America, Europe, and Asia Pacific. METHODS: National agency websites were manually searched (October 2021, updated October-December 2023) to identify standalone PED guidance, and general submission/clinical trial or disease-specific guidance in four therapy areas, including PED-related recommendations. Identified documents were reviewed for requirements/expectations on types of PED; concepts of interest and instruments/tools; validation, analysis, and interpretation; study design, and endpoint definitions. RESULTS: A total of 34 regulatory and 21 HTA documents were reviewed across 7 and 11 agencies, respectively. Most regulatory agencies expected data collected via clinical outcome assessments; concepts of interest were similar; specific tools were not usually recommended, although the use of validated instruments was expected; and meaningful within-patient change was generally considered key to interpretation. HTA guidance on PED varied primarily based on country requirement for utility estimates to inform economic evaluation (little/no guidance beyond the concept of interest) versus interest in PED on signs, symptoms, or disease impact on functioning (generally more comprehensive details on PED expectations). CONCLUSION: Through PED, patient voice is an increasingly important factor in regulatory, access, and reimbursement decision-making. Regulatory and HTA agencies in North America, Europe, and Asia Pacific have varying expectations regarding PED. This misalignment can necessitate the collection of multiple types of PED to meet all requirements (resulting in complex clinical trial protocols and significant patient burden), and lead to differences in data interpretation or gaps in the expected data. Therefore, PED measurement standards should be harmonized globally, and the collection of required PED should be ensured early during drug development to ensure decisions can be made based on valid and reliable data.

Cite this paper

Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.

APA 7

Delbecque, L., Zschocke, J., Ding, D., Poon, J. L., Alonzo, C., Pérez, N. G., Myrick, S., & Hill, J. N. (2025). Identification and Description of Regulatory and Health Technology Assessment Agencies’ Guidance Related to Patient Experience Data in North America, Europe, and Asia Pacific. Therapeutic Innovation & Regulatory Science, 59(6), 1394–1412. https://doi.org/10.1007/s43441-025-00777-z

MLA 9

Delbecque, Laure, et al. “Identification and Description of Regulatory and Health Technology Assessment Agencies’ Guidance Related to Patient Experience Data in North America, Europe, and Asia Pacific.” Therapeutic Innovation & Regulatory Science, vol. 59, no. 6, 2025, pp. 1394–1412. https://doi.org/10.1007/s43441-025-00777-z.

Chicago

Delbecque, Laure, Juergen Zschocke, Ding Ding, Jiat Ling Poon, Carolina Alonzo, Nancy Gabriela Pérez, Shane Myrick, and Jennifer N. Hill. 2025. “Identification and Description of Regulatory and Health Technology Assessment Agencies’ Guidance Related to Patient Experience Data in North America, Europe, and Asia Pacific.” Therapeutic Innovation & Regulatory Science 59 (6): 1394–1412. https://doi.org/10.1007/s43441-025-00777-z.

Harvard

Delbecque, L. et al. (2025) ‘Identification and Description of Regulatory and Health Technology Assessment Agencies’ Guidance Related to Patient Experience Data in North America, Europe, and Asia Pacific’, Therapeutic Innovation & Regulatory Science, 59(6), pp. 1394–1412. doi:10.1007/s43441-025-00777-z.

IEEE

L. Delbecque et al., “Identification and Description of Regulatory and Health Technology Assessment Agencies’ Guidance Related to Patient Experience Data in North America, Europe, and Asia Pacific,” Therapeutic Innovation & Regulatory Science, vol. 59, no. 6, pp. 1394–1412, 2025, doi: 10.1007/s43441-025-00777-z.

BibTeX

@article{delbecque2025identification,
  title     = {{Identification and Description of Regulatory and Health Technology Assessment Agencies’ Guidance Related to Patient Experience Data in North America, Europe, and Asia Pacific}},
  author    = {Delbecque, Laure and Zschocke, Juergen and Ding, Ding and Poon, Jiat Ling and Alonzo, Carolina and Pérez, Nancy Gabriela and Myrick, Shane and Hill, Jennifer N.},
  journal   = {Therapeutic Innovation \& Regulatory Science},
  year      = {2025},
  volume    = {59},
  number    = {6},
  pages     = {1394--1412},
  doi       = {10.1007/s43441-025-00777-z},
  url       = {https://doi.org/10.1007/s43441-025-00777-z}
}

Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)

Topic and keywords

Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Health Systems, Economic Evaluations, Quality of Life

  • patient experience data
  • regulatory guidelines
  • regulatory agencies
  • HTA agencies
  • patient-reported outcome measures
  • economic evaluation
  • patient voice
  • measurement harmonization

Work with this paper

Most-cited papers in Economics, Econometrics and Finance

All highly cited Economics, Econometrics and Finance papers

Questions about this paper

How do I cite this paper in APA style?

Delbecque, L., Zschocke, J., Ding, D., Poon, J. L., Alonzo, C., Pérez, N. G., Myrick, S., & Hill, J. N. (2025). Identification and Description of Regulatory and Health Technology Assessment Agencies’ Guidance Related to Patient Experience Data in North America, Europe, and Asia Pacific. Therapeutic Innovation & Regulatory Science, 59(6), 1394–1412. https://doi.org/10.1007/s43441-025-00777-z

How many times has this paper been cited?

1 times, according to OpenAlex on 22 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.

Is this paper free to read?

Yes. It is open access at Therapeutic Innovation & Regulatory Science: sign in and open the PDF from this page.

Who wrote this paper?

Laure Delbecque, Juergen Zschocke, Ding Ding, Jiat Ling Poon, Carolina Alonzo, Nancy Gabriela Pérez, Shane Myrick, Jennifer N. Hill.

What is the DOI of this paper?

10.1007/s43441-025-00777-z, permanently at https://doi.org/10.1007/s43441-025-00777-z. Sign in and open it from this page.

Bibliographic data from OpenAlex (CC0), last checked 22 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.